- Home
- ZYME vs NSSC Comparison
ZYME vs NSSC Comparison
Compare ZYME & NSSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NSSC
- Stock Information
- Founded
- ZYME 2003
- NSSC 1969
- Country
- ZYME United States
- NSSC United States
- Employees
- ZYME 286
- NSSC N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NSSC Telecommunications Equipment
- Sector
- ZYME Health Care
- NSSC Telecommunications
- Exchange
- ZYME Nasdaq
- NSSC Nasdaq
- Market Cap
- ZYME 739.6M
- NSSC 899.1M
- IPO Year
- ZYME 2017
- NSSC N/A
- Fundamental
- Price
- ZYME $11.53
- NSSC $21.69
- Analyst Decision
- ZYME Buy
- NSSC Strong Buy
- Analyst Count
- ZYME 6
- NSSC 5
- Target Price
- ZYME $19.50
- NSSC $37.00
- AVG Volume (30 Days)
- ZYME 833.8K
- NSSC 529.3K
- Earning Date
- ZYME 05-08-2025
- NSSC 05-05-2025
- Dividend Yield
- ZYME N/A
- NSSC 2.31%
- EPS Growth
- ZYME N/A
- NSSC 12.99
- EPS
- ZYME N/A
- NSSC 1.31
- Revenue
- ZYME $76,304,000.00
- NSSC $186,533,000.00
- Revenue This Year
- ZYME $26.29
- NSSC N/A
- Revenue Next Year
- ZYME $75.78
- NSSC $7.11
- P/E Ratio
- ZYME N/A
- NSSC $16.56
- Revenue Growth
- ZYME 0.38
- NSSC 5.14
- 52 Week Low
- ZYME $7.97
- NSSC $19.00
- 52 Week High
- ZYME $17.70
- NSSC $58.09
- Technical
- Relative Strength Index (RSI)
- ZYME 49.31
- NSSC 42.06
- Support Level
- ZYME $10.69
- NSSC $21.24
- Resistance Level
- ZYME $11.48
- NSSC $22.35
- Average True Range (ATR)
- ZYME 0.78
- NSSC 1.20
- MACD
- ZYME 0.10
- NSSC 0.17
- Stochastic Oscillator
- ZYME 81.57
- NSSC 58.48
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.